The Ally Bridge Group is led by a group of partners who have distinguished backgrounds and complementary experience in private equity, hedge fund, healthcare, finance, operations and management. Mr. Yu is the founder, CEO and CIO of the firm who carries a strong track record as an investment manager across multiple funds and strategies. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.

Since 2010, Mr. Yu has founded, launched and managed 4 funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe.  Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders, between companies in China, the U.S. and Europe, and helping global companies to access the China market while assisting Chinese companies to acquire novel technologies overseas.

  • Alan Chen is a Partner and Managing Director, Head of Private Equity. Alan has over twenty years of financing and investment experience, of which over 10 years has been on private equity investments. Prior to ABG, he had worked with Permira, Goldman Sachs and HSBC. While Alan was Head of China for Permira, he took the lead or participated in many sizeable private equity projects and helped raise capital from institutional investors. Alan made significant contributions in the design and implementation of Permira’s China strategies and other cross-border value-creation initiatives. Alan was at Goldman Sachs (Asia) in Hong Kong during 2002 to 2011 and worked in a number of landmark principal investments and advisory transactions including Goldman Sachs’ investment in Industrial and Commercial Bank of China, Goldman Sachs’ investment in Shuanghui Group (now the WH Group) and HSBC’s strategic investment in Bank of Communications. Alan received his MBA from The Yale School of Management, Master’s Degree in Economics from The Hong Kong University of Science and Technology and Bachelor’s Degree from Fudan University.
  • Anna Yaeger is the portfolio manager of ABG New York office and a Partner of ABG. She is responsible for managing US and European public equity positions managed by ABG. Ms. Yaeger has extensive experience in hedge fund portfolio management. Prior to ABG, Ms. Yaeger spent 12 years at SAC Capital/Point 72. She served as a Portfolio Manager for a $350 million long-short healthcare portfolio for 4 years and was a Senior Research Analyst for a healthcare portfolio prior to that. As a Portfolio Manager, she generated positive absolute and alpha returns for her fund every year. She invested in all sectors in the healthcare space across the US, Europe and Japan. Before joining SAC Capital/Point 72, Ms. Yaeger worked at Goldman Sachs in the Healthcare Investment Banking Group in New York. She graduated magna cum laude from The Wharton School at the University of Pennsylvania with a BS in Economics.
  • Charles Chon is a Partner and Managing Director of Ally Bridge Group. Mr. Chon leads ABG’s Medical Technologies effort and is a member of ABG’s Investment Committee. Before joining ABG in 2013, Mr. Chon had been a healthcare public equity research analyst for over 13 years on both buy-side and sell-side, mostly as Vice President and senior equity research analyst at Goldman Sachs on the US medical devices team. From there, Mr. Chon became the Sector Head for US medical devices research at Stifel Nicolaus. Mr. Chon began his career on Wall Street at ABN AMRO and also covered the healthcare sector from the buy-side at Fred Alger Management. Mr. Chon holds CFA designation, and received his MBA in healthcare management from Boston University and BA in Chemistry from Amherst College.
  • Andrew Pang is a Principal of Ally Bridge Group and focuses on medical devices investments and private equity transactions. He joined the team led by Frank Yu in 2011 and has since played an important role in underwriting and executing notable transactions including the take-private of WuXi Pharmatech and Shandong Luoxin Pharmaceutical as well as the Series C investment in GRAIL, Inc. Before joining ABG, Mr. Pang worked at InterLeader, a family-office investment group in Hong Kong, focusing on private equity transactions. Prior to returning to Hong Kong, Mr. Pang worked at Bank of America in London, where he worked on European leveraged buyout transactions. Mr. Pang has developed excellent deal execution skills and cross-border investment experience. Mr. Pang holds a BA in Mathematics and Computer Science from the University of Cambridge where he graduated with first class honors.
  • Reese Yeh is a Principal of Ally Bridge Group and focuses on private equity transactions and biopharma investments. She joined the team led by Frank Yu in 2012 and has since played an important role in underwriting and executing notable transactions including the take-private of WuXi Pharmatech and the investment in Vifor Pharma. Prior to joining ABG, Ms. Yeh was with Morgan Stanley Private Equity Asia, focusing on private equity transactions in Greater China and Southeast Asia. Ms. Yeh holds a BBA in Finance from National Taiwan University.
  • Dr. Hong Zheng has over 10 years’ of experience in biotechnology, working across the fields of finance, industry and academia. Before joining Ally Bridge Group, Dr. Zheng was a senior equity research associate at Royal Bank of Canada capital markets, covering over 30 US biotech companies. Prior to RBC, Dr. Zheng was a medicinal chemist at Ra Pharmaceuticals for three years, where he led several drug discovery programs including small molecule and peptide drug candidates that later have entered into clinical stage. Dr. Zheng completed his Bachelor’s degree from Fudan University and received his PhD in Chemical Biology from Boston College, where he published many highly impactful research articles in top ranked journals as the first author.
  • Tinnie Chau is a Vice President at Ally Bridge Group and focuses on biopharma and biotech investments. She joined Ally Bridge Group in 2015 and has since participated in the execution as well as portfolio management of all the biopharma investments of the group. Prior to joining ABG, Ms. Chau worked as a Manager at the Corporate Finance department of PwC, providing advisory services on M&A transactions across industries with a number of transactions in the healthcare sector. Ms. Chau holds a BA and MA in Biological Natural Sciences from the University of Cambridge, specialized in Pathology and Microbiology. Ms. Chau is a CFA® Charterholder.
  • Barney Han is a Vice President at Ally Bridge Group and focuses on ABG’s private equity transactions and medical devices investments. Mr. Han joined the ABG platform in 2014 and played an important role in executing notable transactions including the take-private of WuXi Pharmatech and Shandong Luoxin Pharmaceutical. Previously Mr. Han was a private equity investment analyst at LionRock, where he was involved in private equity investments with a particularly strong coverage of China related deals. Mr. Han holds a CFA Level III and FRM II certification and both an MSc in Finance from Hong Kong University as well as a BA in Economics from Nankai University.
  • Katherine Fenwick is the Head of Investor Relations and Operations of the Ally Bridge Group MedAlpha Fund based in New York. Prior to ABG, Ms. Fenwick was the Head of Marketing at Noctua Partners, managing all capital raising efforts for the firm’s Latin American focused hedge fund strategies. Before joining Noctua Partners, Ms. Fenwick worked at Citadel LLC in New York as a member of the Global Distribution team, responsible for establishing and maintaining US institutional relationships. Katherine moved on to help build out the Primary Research Group within Citadel, conducting survey and market research across industries for the firm’s equities businesses. Prior to Citadel, Ms. Fenwick worked at J.P. Morgan in the Leveraged Finance Banking Group in New York. Katherine graduated from Washington and Lee University with a BS in Accounting and Business Administration.
  • Annie Lai, CFA and CPA, is the Partner, Group Chief Operating Officer and Chief Financial Officer. She has 20 years of experience in asset management and 4 years of experience in direct investment in China. Prior to joining ABG in April 2018, she was a Partner of Ward Ferry Management and served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of the group. She spent over 13 years with Ward Ferry and had been instrumental in building the group's infrastructure and teams. During her time in Ward Ferry, she helped Ward Ferry navigate through significant regulatory and tax changes, market crisis and succession management. She is familiar with operational due diligence, SFC and SEC compliance matters. Previously, Annie was the Assistant Director of Finance at Lloyd George Management. Annie is a member of The Hong Kong Institute of CPAs, a CFA charterholder, and received her MBA from The Hong Kong University of Science and Technology.
  • Nelly Kam is the Financial Controller at Ally Bridge Group’s Private Equities business. She has over 10 years of experience in Asset Management including 7 years in private equities. Before joining ABG, she worked for Olympus Capital, a PE firm with over US$2.5 billion specializing in investment across Asia. She started her career as an auditor in Ernst & Young and Deloitte Touche Tohmatsu. Ms. Kam holds the CPA designation, and received her Master in Finance in Chinese University of Hong Kong.
  • Amy Ko oversees the finance and administration function of ABG private equity funds. She has over 7 years of experience in private equity and fund administration. Prior to joining the ABG platform, Ms. Ko spent over 4 years (2011-2016) at CLSA Capital Partners, the Hong Kong-based private equity and venture capital arm of CLSA, specializing in growth companies, real estates and mid-market buyout. Ms. Ko started her career with the Financial Services practice of PricewaterhouseCoopers and subsequently worked with HSBC Fund Services in Hong Kong。 Ms. Ko holds the CPA designation, and received her MBA from the University of Hong Kong and a BBA in Accounting and Management of Organizations from the Hong Kong University of Science and Technology.
  • Windows Fung is the Compliance Manager for Ally Bridge Group. He has over 6 years of experience in both buy-side and sell-side of the financial industry. Prior to joining the ABG platform, Mr. Fung was the Compliance Officer at Ariose Capital Management Limited, a Hong Kong-based, long-short equity Greater China-focus hedge fund manager. Mr. Fung started his career with Goldman Sachs in both the middle office and back office functions and subsequently worked at JP Morgan Chase in Hong Kong in the Compliance Department. Mr. Fung received his BBA in Global Business and Economics from the Hong Kong University of Science and Technology.
  • Mr. Boone, who had dedicated 28 years to Amgen, is one of the most accomplished drug discovery and development scientist in the biotech industry. As Global Head of Protein Science at Amgen, Mr. Boone led the successful development of several blockbuster biologic drugs including Neupogen, Neulasta and N-plate, in addition to his involvement in many other drugs successfully developed at Amgen. Apart from being a highly productive drug discovery scientist with strong biologic manufacturing expertise, Mr. Boone led and mentored a group of over 300 scientists at Amgen. His wealth of biotech knowledge, network and commercial successes are highly valuable to ABG’s investment effort in the biopharmaceutical field, especially in terms of in-depth due diligence and portfolio management.
  • Dr. Li, with over 30 years of experience in the life sciences sector, joins ABG from Pfizer (Boston) where he was Executive Director and Head of Biotherapeutic Technologies. Prior to Pfizer, Dr. Li spent over 18 years at Amgen in pharmaceuticals research and development. Prior to Pfizer, Dr, Li was in the academia, as a clinical professor at the Washington University School of Medicine. Throughout his career, Dr, Li advanced more than three dozen product candidates from discovery, preclinical, manufacturing to clinical development. Dr, Li holds an MD and MS in Pharmacology from Fujian Medical University.
  • Dr. David Nikodem has over 12 years of investment experience as a seasoned investor with a global investment focus across all healthcare sectors. He has been responsible for portfolio construction, risk management and all portfolio decisions with Exane Asset Management in Paris (long/short global healthcare equities and long only European equities), BNP Paribas proprietary desk in New York, Blumberg Capital Management, LLC (long/short U.S. equity healthcare) and Senior Biotechnology Analyst with Orbitex Management Inc. and Acacia Research Investment Corporation. During this period, he managed a total of US$500 million of assets under management in New York and Paris and has accumulated significant experiences in identifying and valuing scientific technologies in healthcare and an in- depth understanding of both the U.S. and European healthcare industries. Dr. Nikodem has consistently picked stocks that generated favorable returns. Prior to healthcare investing, Dr. Nikodem had worked as a patent examiner in biotechnology with the United States Patent & Trademark Office and as a basic science researcher in National Institutes of Health. Dr. Nikodem holds a Ph.D. in Biochemistry and Molecular Biology from Georgetown University and a BA in Chemistry from The University of Virginia.
  • Mr. Bigois started his career in 1997 in London at Wasserstein Perella then moved to the EMEA Healthcare banking groups of Credit Suisse and then Citi. He also worked as Chief Financial Officer of the US / France based specialty addiction disease biotechnology Company DrugAbuse Sciences. Mr. Bigois maintains an extensive and, global network of relationships and routinely executes advisory assignments with the western as well as selected emerging markets players. Mr. Bigois is a graduate of Ecole Centrale Paris (MSc Engineering) and holds an MSc in Finance and Economics of the London School of Economics (British council scholar).